Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 1-25 of 131

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy with or without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Status: Active
Location: 441 locations
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) after Surgery to Remove all Known Sites of Kidney Cancer
Status: Active
Location: 329 locations
Testing the Addition of Stereotactic Radiation Therapy with Immune Therapy for the Treatment of Patients with Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Status: Active
Location: 264 locations
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with Cancer That Has Spread to the Brain
Status: Active
Location: 225 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 480 locations
Testing Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Kidney Cancer, PAPMET2 Trial
Status: Active
Location: 166 locations
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Status: Active
Location: 44 locations
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Status: Active
Location: 17 locations
STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
Status: Active
Location: 15 locations
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Status: Active
Location: 14 locations
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Status: Active
Location: 13 locations
Stereotactic Body Radiation Therapy for the Treatment of Metastatic Renal Cell Carcinoma in Patients with Oligoprogression on Immune Checkpoint Inhibitors
Status: Active
Location: 12 locations
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Status: Active
Location: 11 locations
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Status: Active
Location: 14 locations
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Status: Active
Location: 11 locations
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Status: Active
Location: 11 locations
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Status: Active
Location: 11 locations
Cemiplimab and Fianlimab before Surgery for the Treatment of Patients with Locally Advanced Kidney Cancer Undergoing Nephrectomy
Status: Active
Location: 7 locations
A Study of Nivolumab in Combination with 177Lu-girentuximab for Kidney Cancer, STARTLITE 2 Study
Status: Active
Location: 7 locations
Abemaciclib and Cabozantinib for the Treatment of Stage IV Clear Cell or Translocation-Associated Renal Cell Carcinoma in Patients Refractory to Immune Checkpoint Blockade Treatment
Status: Active
Location: 7 locations
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
Status: Active
Location: 8 locations
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Status: Active
Location: 7 locations
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma that has Spread to the Brain
Status: Active
Location: 7 locations
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Status: Active
Location: 7 locations
Lattice Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Status: Active
Location: 7 locations